Supplementary Figure S1 from First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas

Abstract

(A) Levels of soluble 4-1BB/CD137 and (B) changes in CD8+ T cells from Cycle 1 day 1, in individual patients by dose group.